Triple‑agonist design and receptor structural biology behind GLP‑1/GIP/glucagon peptides like retatrutide
Retatrutide achieved a mean body weight reduction of over 24% in a 48-week Phase 2 trial, a figure that surpassed every single- and dual-agonist result recorded up to that point. That number is not a coinciden…
Read guide →